News articles about Evoke Pharma (NASDAQ:EVOK) have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Evoke Pharma earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave press coverage about the specialty pharmaceutical company an impact score of 44.9814988910934 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the media headlines that may have effected Accern Sentiment’s scoring:

Shares of Evoke Pharma (NASDAQ:EVOK) traded up $0.04 during trading hours on Friday, hitting $2.11. The stock had a trading volume of 188,369 shares, compared to its average volume of 84,385. The stock has a market capitalization of $32.52, a P/E ratio of -2.24 and a beta of 1.26. Evoke Pharma has a twelve month low of $2.07 and a twelve month high of $4.09.

EVOK has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating and issued a $9.00 price target on shares of Evoke Pharma in a report on Tuesday, October 24th. Zacks Investment Research raised Evoke Pharma from a “sell” rating to a “hold” rating in a report on Monday, November 20th. ValuEngine cut Evoke Pharma from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. FBR & Co reissued a “buy” rating and issued a $10.00 price target on shares of Evoke Pharma in a report on Monday, October 30th. Finally, B. Riley reissued a “buy” rating and issued a $10.00 price target on shares of Evoke Pharma in a report on Wednesday, November 15th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $9.14.

WARNING: “Evoke Pharma (EVOK) Earning Somewhat Favorable Press Coverage, Study Shows” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another site, it was copied illegally and republished in violation of US & international copyright & trademark law. The correct version of this piece can be accessed at

Evoke Pharma Company Profile

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Insider Buying and Selling by Quarter for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with's FREE daily email newsletter.